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Abstract
Background: Visual hallucinations occur in various neurological diseases, but are most prominent in Lewy body
dementia, Parkinson’s disease and schizophrenia. The lifetime prevalence of visual hallucinations in patients with
schizophrenia is much more common than conventionally thought and ranges from 24% to 72%. Cortical
acetylcholine (ACh) depletion has been associated with visual hallucinations; the level of depletion being related
directly to the severity of the symptoms. Current understanding of neurobiological visual processing and research
in diseases with reduced cholinergic function, suggests that AChEI’s may prove beneficial in treating visual
hallucinations. This offers the potential for targeted drug therapy of clinically symptomatic visual hallucinations in
patients with schizophrenia using acetylcholinesterase inhibition.
Methods: A systematic review was carried out investigating the evidence for the effects of AChEI’s in treating
visual hallucinations in Schizophrenia.
Results: No evidence was found relating to the specific role of AChEI’s in treating visual hallucinations in this
patient group.
Discussion: Given the use of AChEI’s in targeted, symptom specific treatment in other neuropsychiatric disorders,
it is surprising to find no related literature in schizophrenia patients. The use of AChEI’s in schizophrenia has
investigated effects on cognition primarily with non cognitive effects measured more broadly.
Conclusions: We would suggest that more focused research into the effects of AChEI’s on positive symptoms of
schizophrenia, specifically visual hallucinations, is needed.
Background
Visual hallucinations are a well recognised and distres-
sing symptom in a variety of psychiatric disorders
including psychotic illness and dementia. The pathophy-
siology of the visual hallucinatory experience remains
unclear and available pharmacological treatments are
disorder rather than symptom specific. Visual hallucina-
tions occur in various neurological diseases, but are
most prominent in Lewy body dementia, Parkinson’s
disease and schizophrenia. The lifetime prevalence of
visual hallucinations in patients with schizophrenia is
thought to be more common than conventionally
thought and estimates range from 24% to 72% [1,2].
Both dopaminergic and cholinergic perturbation have
been associated with visual hallucinations, although
neither of these offers a parsimonious aetiological
model. More recent interest has been associated with
t h er o l eo fc o r t i c a la c e t y l c holine (ACh) depletion and
it’s association with visual hallucinations; the level of
depletion being thought to relate directly to the severity
of the symptoms.
As with many cognitive processes, it is not entirely
clear how the brain processes elementary visual stimuli
and converts them into meaningful percepts; often in
conditions of high ambiguity. A mechanism for this pro-
cess could offer a route into understanding the basis of
visual hallucinatory experiences. An elegant solution to
this problem is offered by neuro-computational models
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any medium, provided the original work is properly cited.based on Bayesian statistical principles, conceptualising
visual processing through a hierarchical system enabling
the human brain to function in environments of uncer-
tainty [3,4]. Ascending, stimulus driven (bottom-up) and
descending, context driven (top-down) pathways com-
bine in an iterative manner to produce an accurate
visual experience of our surroundings. Thus higher cen-
tres form predictions in anticipation of ascending signals
allowing the visual system to process large amounts of
objectively ambiguous information into accurate per-
cepts. Yu and Dayan’s 2002 review of acetylcholine in
cortical inference hypothesises that acetylcholine plays a
pivotal neuro-modulatory role in this top-down/bottom-
up model [5]. It is proposed that acetylcholine in the
human brain modulates the interaction between top-
down and bottom-up processing in determining appro-
priate neural representations for inputs with the levels
of ACh reflecting the uncertainty associated with top-
down information processing [5]. According to this the-
ory, low levels of cortical ACh would result in the
increased salience of top-down information whereas
high levels would result in over-processing of bottom-
up, stimulus driven information. Using this model, visual
hallucinations in ACh depleted cortices could be experi-
enced due to over processing of top down signal and
the resulting undue confidence in experiencing percept
in the absence of sufficient visual stimuli strength [5]. In
addition, dopaminergic neuro-modulation of cholinergic
function is also considered in this review and contem-
porary dopaminergic theories of schizophrenia may be
integrated into this pathway to conceptualise the forma-
tion of visual hallucinations in schizophrenia [6].
Conditions with underlying cholinergic deficits and
high rates of visual hallucinations include Alzheimer’s
disease, dementia with Lewy bodies and Parkinson’s dis-
ease. Targeted drug therapy of the cholinergic system in
these conditions in order to treat visual hallucinations
has shown benefit with AChEI’s [7-12]. Much of this
evidence is from case series’ and randomised control
trials assessing the efficacy of AChEI’s on non cognitive
symptoms broadly, rather than visual hallucinations
specifically.
Applying current understanding of the cholinergic
system in visual pathways and the evidence that AChEI’s
are of use in treating visual hallucinations in the condi-
tions mentioned, it would appear feasible that they
could also be used in schizophrenia related visual hallu-
cinations. In this article, we review the use of AChEI’s
for the targeted treatment of visual hallucinations in
schizophrenia.
Methods
MEDLINE and EMBASE searches were performed using
the search terms, schizophrenia or schizoaffective
disorder and visual hallucinations and acetylcholinester-
ase inhibitors or donepezil or Aricept® or galantamine
or Reminyl® or rivastigmine or Exelon®. No time limits
were set when searching.
As this preliminary search found few articles of interest,
a second wider search was conducted omitting the terms
schizophrenia or schizoaffective disorder. The resulting
articles were then assessed on an individual basis indepen-
dently by two authors. Only those articles which investi-
gated, commented on or case reported the targeted
treatment of visual hallucinations in schizophrenia with
AChEI’s were included.
Results
Our preliminary search found 3 articles. All 3 were not
relevant to our objectives and related to Charles Bonnet
Syndrome, Parkinson’s disease and hypothetical model-
ling of visual hallucinations.
Our second search yielded 205 articles. After removal
of duplicates, we again found no articles of relevance to
our objectives. The majority of articles related to visual
hallucinations in dementing illnesses and Parkinson’s
disease; including case reports, reviews and RCT’s.
Additional file 1 gives an overview of our searches
according to PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guidelines.
Discussion
The results show that there is no direct evidence in the
literature assessing the use of AChEI’s in treating visual
hallucinations in Schizophrenia. Our review was deliber-
ately narrow in keeping with our objectives in order to
identify a symptom specific treatment.
Studies of AChEI’s use in schizophrenia tend to focus
on cognitive symptoms as the primary area of investiga-
tion and non cognitive symptoms as a secondary area;
the later includes psychopathology such as hallucina-
tions and delusions. A recent systematic review and
meta-analysis of the use of AChEI’sa sa na d j u n c t i v e
therapy in schizophrenia and schizoaffective disorder
reported on their effects on psychopathology [13]. The
authors found no statistically significant effect on the
total Positive and Negative Syndrome Scale (PANSS)
scores in those treated with AChEI’s. This conclusion
however may reflect on the chronicity and general clini-
cal stability of the patient’s included in these studies
with a resultant lack of psychopathology at baseline.
There were also a relatively small number of suitable
studies for inclusion in the meta-analysis and therefore
positive effects may have been more difficult to detect.
Given the use of AChEI’s in targeted, symptom speci-
fic treatment in other neuropsychiatric disorders, it is
surprising to find no related literature in schizophrenia.
Studies have understandably focused on the cognitive
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suggest however that more focused research into the
effects of AChEI’s on positive symptoms of schizophre-
nia, specifically visual hallucinations, is needed.
Conclusions
Complex treatment-resistant patients are often left with
residual symptoms, even after compliance with adequate
doses of antipsychotic medication. In the absence of the
advent of a superior novel antipsychotic to clozapine, a
symptom based approach based on the best available
research in other clinical disorders may provide some
guidance in adjunct therapy. Novel therapies falling out-
side usual clinical practice may be necessary, with careful
monitoring, both of clinical efficacy and of toxicity. This
review aims to highlight the need for careful considera-
tion of using AChEI’s in treating non cognitive symptoms
of schizophrenia, more specifically, visual hallucinations.
It certainly highlights the need for studies investigating
the use of adjunctive AChEI’s for targeting specific resi-
dual positive symptoms in addition to continued investi-
gation of their effects on cognitive symptoms.
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